Ruxolitinib for Polycythemia Vera Intolerant or Resistant to Hydroxyurea : Episode 7

Key Takeaways Following MAJIC-PV

May 22, 2024

By Gabriela Hobbs, MD
Timothy Mok, PharmD, BCPS, BCOP

Opinion

Video

Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP, close the discussion with key takeaways for payers to consider related to ruxolitinib and insights on future research.

EP: 1.Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera

EP: 2.The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance

EP: 3.Objectives and Study Design of MAJIC-PV

EP: 4.Inside MAJIC-PV: A Closer Look at the Patient Population

EP: 5.Key Findings from MAJIC-PV

EP: 6.Safety Analysis and Interpreting Results from MAJIC-PV

Now Viewing

EP: 7.Key Takeaways Following MAJIC-PV

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!